Haleos Labs Limited

Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 4 March 2026. This revision reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, signalling a cautious but more optimistic outlook for investors amid mixed fundamental signals.

Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Haleos Labs Limited (NSE: HALEOSLABS), a micro-cap pharmaceutical company with a market capitalisation of ₹379.42 crores, delivered its strongest quarterly performance in Q3 FY26 (October-December 2025), posting consolidated net profit of ₹6.62 crores—an 8.52% quarter-on-quarter increase and a robust 21.02% year-on-year growth. The Hyderabad-based company, which operates in the highly competitive pharmaceuticals and biotechnology sector, saw its stock trading at ₹1,255.00 as of February 12, 2026, down 1.27% on the day but reflecting a complex narrative of operational improvement amidst valuation concerns.

Haleos Labs Limited has seen its investment rating upgraded from Sell to Hold as of 2 February 2026, reflecting a notable improvement in its technical indicators and valuation metrics. Despite lingering concerns over long-term fundamentals, recent quarterly financial performance and a shift in market sentiment have contributed to a more balanced outlook for this pharmaceuticals and biotechnology company.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 1 Feb 2026, closing at ₹1240.0, marking a maximum daily gain of 4.91%. This sharp rally was driven by robust buying interest despite subdued trading volumes and a regulatory freeze on further price movement, reflecting strong investor sentiment amid sector headwinds.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 26 Dec 2025, hitting the lower circuit limit and registering one of the steepest single-day declines in recent times. The stock’s performance contrasted sharply with broader market indices and its sector peers, reflecting a wave of panic selling and unfilled supply on the trading floor.

Haleos Labs Limi has undergone a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial developments and valuation considerations. The pharmaceutical and biotechnology company’s assessment now indicates a more balanced outlook, influenced by changes across quality, valuation, financial trends, and technical factors.

Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 18 Dec 2025, hitting the lower circuit limit and registering a maximum daily loss of 5.0%. The stock closed at ₹1,232.4, marking a significant decline amid subdued investor participation and unfilled supply on the order books.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 17 Dec 2025 as the stock hit its lower circuit limit, reflecting intense selling pressure and a maximum daily loss of 5.0%. The stock’s performance notably lagged behind its sector and broader market indices, signalling a day marked by panic selling and unfilled supply.

Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation following a combination of recent financial results and technical market indicators. The company’s performance over various timeframes, alongside its valuation and technical trends, has prompted a nuanced reassessment of its investment profile.

Haleos Labs Limited has recently experienced a significant technical event known as the Golden Cross, where its 50-day moving average has crossed above the 200-day moving average. This development is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company.

SMS Lifesciences India has experienced a notable revision in its market evaluation, reflecting changes across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This comprehensive review examines the factors influencing the current market perspective on the pharmaceutical and biotechnology company.